Therapeutic plasma concentrations of antidepressants and antipsychotics: Lessons from PET imaging

Pharmacopsychiatry

Volumn 44, Issue 6, 2011, Pages 236-248

  Grunder G ^a,c   Hiemke, C ^b   Paulzen, M ^a   Veselinovic, T ^a   Vernaleken, I ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JARA Translational Brain Medicine   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

antidepressant; antipsychotic; plasma concentration; positron emission tomography (PET); therapeutic drug monitoring (TDM)

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

AKATHISIA; ATTENTION DEFICIT DISORDER; COGNITION; CORPUS STRIATUM; DEPRESSION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG TARGETING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG MONITORING; HUMANS; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY;

EID: 80053384000     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1286282     Document Type: Review

References (72)

1. Alderman J, Wolkow R, Fogel I M. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol: 2006; 16 117 129
2. Argyeln M, Szab Z, Kany B et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord: 2005; 89 115 123
3. Baron J C, Martinot J L, Cambon H et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl): 1989; 99 463 472 (Pubitemid 19273100)
4. Baumann P, Hiemke C, Ulrich S et al. Arbeitsgemeinschaft fr Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry: 2004; 37 243 265 (Pubitemid 39587052)
5. Bench C J, Lammertsma A A, Dolan R J et al. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology Berl: 1993; 112 308 314 (Pubitemid 23278294)
6. Bench C J, Lammertsma A A, Grasby P M et al. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl): 1996; 124 141 147 (Pubitemid 26112782)
7. Bowie C R, Reichenberg A, Patterson T L et al. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry: 2006; 163 418 425 (Pubitemid 44469383)
8. Bressan R A, Erlandsson K, Jones H M et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry: 2003; 160 1413 1420 (Pubitemid 41070915)
9. Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol: 1993; 13 25 40 (Pubitemid 23030357)
10. Daniel D G, Zimbroff D L, Potkin S G et al. Ziprasidone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacol: 1999; 20 491 505
11. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry: 1992; 49 538 544
12. Farde L, Wiesel F A, Halldin C et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry: 1988; 45 71 76 (Pubitemid 18018572)
13. Fischman A J, Bonab A A, Babich J W et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther: 1996; 279 939 947 (Pubitemid 27166871)
14. Fitzgerald P B, Kapur S, Remington G et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl): 2000; 149 1 5 (Pubitemid 30187359)
15. Gallezot J D, Weinzimmer D, Nabulsi N et al. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage: 2010; Sep 29. [Epub ahead of print]
16. Gefvert O, Bergstrm M, Lngstrm B et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl): 1998; 135 119 126 (Pubitemid 28055494)
17. Gefvert O, Lundberg T, Wieselgren I M. et al. D (2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol: 2001; 11 105 110 (Pubitemid 32335553)
18. Ginovart N, Wilson A A, Hussey D et al. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacol: 2009; 34 662 671
19. Goff D C. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients quality of life. Am J Psychiatry: 2008; 165 940 943
20. Grnder G, Carlsson A, Wong D F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry: 2003; 60 974 977 (Pubitemid 37222078)
21. Grnder G, Fellows C, Janouschek H et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry: 2008; 9165 988 995
22. Grnder G, Landvogt C, Vernaleken I et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacol: 2006; 31 1027 1035
23. Hagberg G, Gefvert O, Bergstrm M et al. N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res: 1998; 82 147 160 (Pubitemid 28341799)
24. Hiemke C, Baumann P, Bergemann N et al. The TDM group of the AGNP. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry. Update 2011. Pharmacopsychiatry: 2011; 44 195 235
25. Jensen N H, Rodriguiz R M, Caron M G et al. N-desalkylquetiapine a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapines antidepressant activity. Neuropsychopharmacol: 2008; 33 2303 2312
26. Kapur S, Remington G, Zipursky R B et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci: 1995; 57 PL103 PL107
27. Kapur S, Zipursky R, Jones C et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry: 2000; 57 553 559 (Pubitemid 30349435)
28. Kapur S, Zipursky R B, Remington G et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry: 1998; 155 921 928 (Pubitemid 28307604)
29. Kapur S, Zipursky R, Roy P et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl): 1997; 131 148 152 (Pubitemid 27261602)
30. Keck P Jr, Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl): 1998; 140 173 184 (Pubitemid 28538477)
31. Keefe R S, Bilder R M, Davis S M et al. CATIE Investigators; Neurocognitive Working Group Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry: 2007; 64 633 647 (Pubitemid 46878665)
32. Kegeles L S, Slifstein M, Frankle W G et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacol: 2008; 33 3111 3125
33. Kessler R M, Ansari M S, Riccardi P et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacol: 2006; 31 1991 2001
34. Learned-Coughlin S M, Bergstrm M, Savitcheva I et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry: 2003; 54 800 805 (Pubitemid 37205131)
35. Logan J, Wang G J, Telang F et al. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol: 2007; 34 667 679 (Pubitemid 47248280)
36. Lundberg J, Christophersen J S, Petersen K B et al. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol: 2007; 10 777 785 (Pubitemid 350035825)
37. Mamo D, Kapur S, Keshavan M et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacol: 2008; 33 298 304 (Pubitemid 350243350)
38. Mamo D, Kapur S, Shammi C M et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry: 2004; 161 818 825 (Pubitemid 38625334)
39. Mamo D C, Uchida H, Vitcu I et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry: 2008; 69 81 86 (Pubitemid 351282000)
40. Martinot J L, Paillere-Martinot M L, Poirier M F et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology Berl: 1996; 124 154 158 (Pubitemid 26112784)
41. Medori R, Mannaert E, Grnder G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol: 2006; 16 233 240
42. Meisenzahl E M, Schmitt G, Grnder G et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry: 2008; 41 169 175
43. Meyer J H, Goulding V S, Wilson A A et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl): 2002; 163 102 105 (Pubitemid 34985318)
44. Meyer J H, Wilson A A, Sagrati S et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry: 2004; 161 826 835 (Pubitemid 38625335)
45. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs: 2010; 11 802 812
46. Nordstrm A L, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl): 1992; 106 433 438
47. Nordstrm A L, Farde L, Wiesel F A et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry: 1993; 33 227 235 (Pubitemid 23091497)
48. Nyberg S, Eriksson B, Oxenstierna G et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry: 1999; 156 869 875 (Pubitemid 29260341)
49. Nyberg S, Farde L, Eriksson L et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology: 1993; 110 265 272 (Pubitemid 23051126)
50. Nyberg S, Farde L, Halldin C A. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacol: 1997; 16 1 7 (Pubitemid 27030990)
51. Nyberg S, Farde L, Halldin C et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry: 1995; 152 173 178
52. Pilowsky L S, Mulligan R S, Acton P D et al. Limbic selectivity of clozapine. Lancet: 1997; 350 490 491
53. Reis M, Aamo T, Spigset O et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit: 2009; 31 42 56
54. Remington G, Mamo D, Labelle A et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry: 2006; 163 396 401 (Pubitemid 44469380)
55. Schooler N, Rabinowitz J, Davidson M et al. Early Psychosis Global Working Group Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry: 2005; 162 947 953 (Pubitemid 40676208)
56. Seeman P, Lee T, Chau-Wong M et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature: 1976; 261 717 719
57. Shams M E, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther: 2006; 31 493 502 (Pubitemid 44337299)
58. Suhara T, Takano A, Sudo Y et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry: 2003; 60 386 391 (Pubitemid 36402999)
59. Suzuki Y, Fukui N, Sawamura K et al. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol: 2008; 28 325 328
60. Takano A, Gulys B, Varrone A et al. Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2). Eur J Nucl Med Mol Imaging: 2009; 36 1308 1314
61. Takano A, Suhara T, Kusumi I et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry: 2006; 30 75 81 (Pubitemid 43021324)
62. Takano A, Suzuki K, Kosaka J et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl): 2006; 185 395 399
63. Uchida H, Mamo D C, Kapur S et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry: 2008; 69 1281 1286
64. Ulrich S, Neuhof S, Braun V et al. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry: 1998; Sep; 31 05 163 169 (Pubitemid 28505907)
65. Vernaleken I, Fellows C, Janouschek H et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol: 2008; 28 608 617
66. Vernaleken I, Janouschek H, Raptis M et al. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol: 2010; 13 951 960
67. Vernaleken I, Siessmeier T, Buchholz H G et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol: 2004; 7 421 430 (Pubitemid 39648072)
68. Voineskos A N, Wilson A A, Boovariwala A et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl): 2007; 193 539 545 (Pubitemid 47094376)
69. Wolkin A, Barouche F, Wolf A P et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry: 1989; 146 905 908 (Pubitemid 19180972)
70. Wong D F, Tauscher J, Grnder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacol: 2009; 34 187 203
71. Xiberas X, Martinot J L, Mallet L et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol: 2001; 21 207 214 (Pubitemid 32221059)
72. Yokoi F, Grnder G, Biziere K et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacol: 2002; 27 248 259 (Pubitemid 34692591).